NCT00382629View on ClinicalTrials.gov

BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

February 28, 2006

Study Completion Date

June 30, 2007

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

BHT-3009 0.5 mg

DRUG

BHT-3009 1.5 mg

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Bayhill Therapeutics

INDUSTRY

NCT00382629 - BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter